Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 19Recruiting 14Terminated 8Unknown 5Active not recruiting 4Withdrawn 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1CNS 1

Conditions

Rhabdoid Tumor 1Neuroectodermal Tumors, Primitive 1Medulloblastoma 1Leukemia, Myeloid, Acute 1Glioma 1Ependymoma 1Choroid Plexus Carcinoma 1Brain Neoplasms 1

Interventions

Cyclophosphamide 129Cisplatin 119Radiotherapy 115pembrolizumab 111Carboplatin 97Paclitaxel 96Gemcitabine 96Magnetic Resonance Spectroscopy 80Nivolumab 76Bevacizumab 76Fluorouracil 74Dexamethasone 73Radiosurgery 66Docetaxel 59Rituximab 58Leucovorin 57Oxaliplatin 55Capecitabine 55Biopsy 53Doxorubicin 52fludarabine 51Drug Therapy 45durvalumab 44Cytarabine 44Etoposide 42fludarabine phosphate 40Pemetrexed 40Radiation 39atezolizumab 36Surveys and Questionnaires 36

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Hematopoietic Stem Cell Transplantation × Clear all
NCT04521946 2024-10-26

Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer

M.D. Anderson Cancer Center

Phase 1 Withdrawn
CNS

Choroid Plexus Carcinoma, Brain Neoplasms, Ependymoma, Glioma, Medulloblastoma, Neuroectodermal Tumors, Primitive, Rhabdoid Tumor

NCT03881735 2021-03-10

Enasidenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia With an IDH2 Gene Mutation

Roswell Park Cancer Institute

Phase 2 Withdrawn
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡